Functional characterization of a chimeric lipase genetically engineered from human lipoprotein lipase and human hepatic lipase.
Lipoprotein lipase (LPL) and hepatic lipase (HL) mediate the hydrolysis of triglycerides and phospholipids present in circulating lipoprotein particles and are essential for normal lipid metabolism. Both enzymes have a similar primary amino acid structure and share requirements for intact catalytic, lipid binding, and heparin binding domains. However, LPL and HL exhibit different substrate specificities and cofactor requirements. In order to characterize the functional domains necessary for LPL activity, a chimeric lipase consisting of the amino-terminal 314 amino acids of human LPL and the carboxyl-terminal 146 amino acids of human HL was synthesized by joining the cDNA of both lipases at the 5'-end of exon 7. Northern blot hybridization and Western blot analyses revealed the size of the chimera mRNA and protein to be approximately 1.5 kb and 55 kDa, respectively. The chimeric enzyme hydrolyzed both long chain and short chain fatty acid triacylglycerols and had catalytic properties that were similar to lipoprotein lipase. Thus, apolipoprotein (apo)C-II was required for maximal lipase activity, and high salt concentration abolished the ability of the chimera to hydrolyze triolein even in the presence of apoC-II. A monospecific anti-HL polyclonal antibody interacting with the C-terminal HL-derived domain of the chimeric enzyme abolished the enzyme's ability to hydrolyze triglyceride emulsion but not tributyrin substrates. Analysis of the heparin binding properties of the chimeric enzyme using heparin-Sepharose affinity chromatography revealed an elution pattern which was intermediate between that of lipoprotein and hepatic lipase. In summary, we have characterized the functional properties of an LPL-HL chimeric enzyme.(ABSTRACT TRUNCATED AT 250 WORDS)
Dichek
H L
HL
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Parrott
C
C
Ronan
R
R
Brunzell
J D
JD
Brewer
H B
HB
Santamarina-Fojo
S
S
D001483:Base Sequence; D001665:Binding Sites; D002384:Catalysis; D002460:Cell Line; D017077:Culture Media, Conditioned; D004622:Embryo, Mammalian; D005227:Fatty Acids / Q000378:metabolism; D005818:Genetic Engineering; D006493:Heparin / Q000378:metabolism; D006801:Humans; D007668:Kidney; D008049:Lipase / Q000235:genetics / Q000378:metabolism*; D008071:Lipoprotein Lipase / Q000235:genetics*; D008099:Liver / Q000201:enzymology*; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000378:metabolism*; D013379:Substrate Specificity; D014162:Transfection; D014280:Triglycerides / Q000378:metabolism; D014304:Triolein / Q000378:metabolism
D017077:Culture Media, Conditioned; D005227:Fatty Acids; D011993:Recombinant Fusion Proteins; D014280:Triglycerides; D014304:Triolein; D006493:Heparin; D008049:Lipase; D008071:Lipoprotein Lipase; C005830:tributyrin